<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="55828"><DrugName>naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), AstraZeneca/Old API Wind-down</DrugName><DrugNamesKey><Name id="42909783">Vimovo</Name></DrugNamesKey><DrugSynonyms><Name><Value>naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), AstraZeneca/POZEN</Value></Name><Name><Value>naproxen + esomeprazole</Value></Name><Name><Value>naproxen + esomeprazole (osteoarthritis/rheumatoid arthritis pain), AstraZeneca/POZEN</Value></Name><Name><Value>PN-400</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Vimovo</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>PN-40020</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>naproxen + esomeprazole magnesium</Value></Name><Name><Value>naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), AstraZeneca/Aralez</Value></Name><Name><Value>naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), Grunenthal/Horizon</Value></Name><Name><Value>naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), AstraZeneca/Old API Wind-down</Value></Name><Name><Value>22204-53-1</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>119141-88-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25618">POZEN Inc</CompanyOriginator><CompaniesPrimary><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Company id="16587">Grunenthal GmbH</Company></CompaniesPrimary><CompaniesSecondary><Company id="1053335">Horizon Pharma plc</Company><Company id="14190">AstraZeneca plc</Company><Company id="25618">POZEN Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55828" type="Drug"><TargetEntity id="446226" type="siDrug">Esomeprazole magnesium/naproxen</TargetEntity></SourceEntity><SourceEntity id="1053335" type="Company"><TargetEntity id="5037276891" type="organizationId">Horizon Therapeutics PLC</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="15713" type="Company"><TargetEntity id="4295862549" type="organizationId">Nuvo Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="16587" type="Company"><TargetEntity id="4296790654" type="organizationId">Gruenenthal GmbH</TargetEntity></SourceEntity><SourceEntity id="25618" type="Company"><TargetEntity id="4295901542" type="organizationId">POZEN Inc</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"/><TargetEntity id="D010003" type="MeSH"/><TargetEntity id="-478836143" type="omicsDisease"/><TargetEntity id="747" type="siCondition"/></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="3003" type="ciIndication"><TargetEntity id="M08.0" type="ICD10"/><TargetEntity id="D001171" type="MeSH"/><TargetEntity id="-1334562803" type="omicsDisease"/><TargetEntity id="750" type="siCondition"/></SourceEntity><SourceEntity id="398" type="ciIndication"><TargetEntity id="M45" type="ICD10"/><TargetEntity id="720.0" type="ICD9"/><TargetEntity id="10002556" type="MEDDRA"/><TargetEntity id="D013167" type="MeSH"/><TargetEntity id="-605402220" type="omicsDisease"/><TargetEntity id="752" type="siCondition"/></SourceEntity><SourceEntity id="208" type="Action"><TargetEntity id="434" type="Mechanism">H+/K+-ATPase Inhibitors</TargetEntity><TargetEntity id="2955" type="Mechanism">Reversible H+/K+-ATPase Inhibitors </TargetEntity></SourceEntity><SourceEntity id="132" type="Action"><TargetEntity id="405" type="Mechanism">Cyclooxygenase (COX) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Ankylosing spondylitis - US - Jul-2010</FirstLaunched><FirstLaunched>Osteoarthritis - US - Jul-2010</FirstLaunched><FirstLaunched>Pain - US - Jul-2010</FirstLaunched><FirstLaunched>Rheumatoid arthritis - US - Jul-2010</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="20">Pain</Indication><Indication id="245">Osteoarthritis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="398">Ankylosing spondylitis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="3003">Juvenile rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="132">Cyclooxygenase inhibitor</Action><Action id="208">H+ K+ ATPase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="329">Prostaglandin synthesis inhibitor</Action><Action id="2955">Non-steroidal anti-inflammatory</Action><Action id="2946">Analgesic</Action><Action id="182">Gastric secretion inhibitor</Action><Action id="38200">Acid pump inhibitor antiulcerant product</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="585">Oral formulation</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="661">Oral quick release formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>M1A3</Code><Name>Coxibs</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-20T09:47:27.000Z</LastModificationDate><ChangeDateLast>2019-05-16T00:00:00.000Z</ChangeDateLast><AddedDate>2006-08-03T14:31:52.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="25618" linkType="Company"&gt;POZEN&lt;/ulink&gt; (now  &lt;ulink linkID="1110015" linkType="Company"&gt;Old API Wind-down&lt;/ulink&gt; (formerly Aralez Pharmaceuticals following the merger of POZEN with &lt;ulink linkID="27990" linkType="Company"&gt;Tribute Pharmaceuticals Canada&lt;/ulink&gt;) and &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; (AZ), and now marketed by &lt;ulink linkID="16587" linkType="Company"&gt;Grunenthal&lt;/ulink&gt; and &lt;ulink linkID="15713" linkType="Company"&gt;Nuvo Pharmaceuticals&lt;/ulink&gt;, Vimovo (PN-400; PN-40020) is an oral, fixed-dose combination of a delayed-release enteric-coated  NSAID naproxen (500 mg) and 	immediate-release  proton pump inhibitor &lt;ulink linkID="16026" linkType="Drug"&gt;esomeprazole&lt;/ulink&gt; (20 mg). In the EU, the product is indicated   in adults for the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient [&lt;ulink linkID="2095200" linkType="Reference"&gt;2095200&lt;/ulink&gt;]. In the US, the combination is indicated in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers. The naproxen component of Vimovo is indicated for relief of signs and symptoms of: OA; RA and AS in adults; and Juvenile idiopathic arthritis (JIA) in adolescent patients. The esomeprazole magnesium component of Vimovo is indicated to decrease the risk of developing naproxen-associated gastric ulcers [&lt;ulink linkID="1095696" linkType="Reference"&gt;1095696&lt;/ulink&gt;], [&lt;ulink linkID="1496998" linkType="Reference"&gt;1496998&lt;/ulink&gt;], [&lt;ulink linkID="1732750" linkType="Reference"&gt;1732750&lt;/ulink&gt;], [&lt;ulink linkID="2117348" linkType="Reference"&gt;2117348&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;US launch took place in July 2010 for use in patients with RA, OS and AS in adults [&lt;ulink linkID="1176104" linkType="Reference"&gt;1176104&lt;/ulink&gt;]; in  July 2017, the drug was additionally approved  in the US  for the treatment of adolescent patients with JIA [&lt;ulink linkID="2095205" linkType="Reference"&gt;2095205&lt;/ulink&gt;]. By May 2011, launch had occurred in the UK [&lt;ulink linkID="1189017" linkType="Reference"&gt;1189017&lt;/ulink&gt;];  and by July 2011, the product was being marketed in nine European countries [&lt;ulink linkID="1210869" linkType="Reference"&gt;1210869&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The Orange Book lists 12 patents relevant to Vimovo. Among them, &lt;ulink linkID="PA2902324" linkType="Patent"&gt;US-06369085&lt;/ulink&gt; includes claims related to the drug substance, drug product and method of use, and pediatric exclusivity expires on November 25, 2018, and &lt;ulink linkID="PA3009290" linkType="Patent"&gt;US-06926907&lt;/ulink&gt;  includes claims directed to the formulation and its use in the relief of arthritis and risk reduction of gastric ulcer (expiry February 2023). In March 2016, the USPTO issued a Notice of Allowance for  US patent application number 14/954,082. The issued patent expires in May 2022. Following issuance, Horizon and Aralez planned to list the patent in the FDA Orange Book [&lt;ulink linkID="1743123" linkType="Reference"&gt;1743123&lt;/ulink&gt;]. In June 2016, the USPTO issued another Notice of Allowance for  US patent application number 14/980,639. The US patent scheduled to issue from the application will expire in September 2029 and covers methods of delivery of the delayed-release, fixed-dose combination. Following issuance, Horizon and Aralez  planned to list the patent in the FDA Orange Book [&lt;ulink linkID="1768412" linkType="Reference"&gt;1768412&lt;/ulink&gt;]. In March 2017, the USPTO issued a notice of allowance for patent application 15/180,173, covering naproxen/esomeprazole delayed release tablets; once issued, the patent was to be listed in the Orange Book and would expire in May 2022 [&lt;ulink linkID="1913504" linkType="Reference"&gt;1913504&lt;/ulink&gt;]. In February 2017, Horizon stated it held licenses to US patents and patent applications covering Vimovo, and that the in-licensed patents expire between 2018 and 2031 [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;]. In June 2017,  the product was covered by 14 Orange Book-listed patents, including &lt;ulink linkID="PA6793423" linkType="Patent"&gt;US-08557285&lt;/ulink&gt; set to expire in May 2022   [&lt;ulink linkID="1941209" linkType="Reference"&gt;1941209&lt;/ulink&gt;], [&lt;ulink linkID="1941423" linkType="Reference"&gt;1941423&lt;/ulink&gt;]. In March 2018, Aralez noted that together with AstraZeneca, a joint patent applications relating to Vimovo had been filed, and an issued US patent related to the pharmacodynamics profile of Vimovo is to expire in October 2031. Additionally, Aralez had also two issued US patents related to methods of treatment with Vimovo in patients taking low dose aspirin, which are to expire as late as March 2031  [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2018, Aralez entered into an amendment to the license agreement with Horizon for Vimovo in the US to  allow Horizon to settle patent litigations without Aralez's consent in certain circumstances. In March 2018, litigation with respect to several patents covering Vimovo was ongoing [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, &lt;ulink linkID="29387" linkType="Company"&gt;Dr Reddy's Laboratories&lt;/ulink&gt; filed an ANDA for a generic version. In April 2011, POZEN and AZ responded by filing a US lawsuit against Dr Reddy's alleging  infringement of US-06926907 [&lt;ulink linkID="1186220" linkType="Reference"&gt;1186220&lt;/ulink&gt;]. Dr Reddys subsequently amended its filing to include Paragraph IV certifications against five additional patents [&lt;ulink linkID="1726316" linkType="Reference"&gt;1726316&lt;/ulink&gt;]. In September 2013, Dr Reddy’s received FDA approval for its generic version of Vimovo (20 mg/375 mg and 20 mg/500 mg) [&lt;ulink linkID="1413005" linkType="Reference"&gt;1413005&lt;/ulink&gt;]. In February 2015,  Dr Reddy’s filed a petition for inter partes review of US-08557285; in October 2015, the USPTO denied the petition. In February 2016, Horizon amended the complaint against Dr Reddy’s to include infringement allegations concerning &lt;ulink linkID="PA8156417" linkType="Patent"&gt;US-09161920&lt;/ulink&gt; and &lt;ulink linkID="PA8397309" linkType="Patent"&gt;US-09198888&lt;/ulink&gt;. In May 2016, a US District Court granted Dr Reddy’s motion for summary judgment of non-infringement of US-06926907 with respect to one of Dr Reddy’s two ANDAs. In August 2016, Horizon filed new a complaint alleging infringement of &lt;ulink linkID="PA6301561" linkType="Patent"&gt;US-08945621&lt;/ulink&gt;, &lt;ulink linkID="PA5531633" linkType="Patent"&gt;US-09220698&lt;/ulink&gt; and &lt;ulink linkID="PA8588661" linkType="Patent"&gt;US-09345695&lt;/ulink&gt; against Dr Reddy’s. In October 2016,  Dr Reddy’s filed  a motion to dismiss all counts in Case II (consists of the cases asserting &lt;ulink linkID="PA7860674" linkType="Patent"&gt;US-08858996&lt;/ulink&gt;, &lt;ulink linkID="PA7860625" linkType="Patent"&gt;US-08865190&lt;/ulink&gt;, &lt;ulink linkID="PA7789634" linkType="Patent"&gt;US-08852636&lt;/ulink&gt;, &lt;ulink linkID="PA8156417" linkType="Patent"&gt;US-09161920&lt;/ulink&gt; and &lt;ulink linkID="PA8397309" linkType="Patent"&gt;US-09198888&lt;/ulink&gt;) and a motion for summary judgment relevant to Cases I (consists of the cases asserting US-08557285 and US-06926907), II and III (consists of the cases asserting US-08945621, US-09220698, US-09345695, and the &lt;ulink linkID="PA8632592" linkType="Patent"&gt;US-09393208&lt;/ulink&gt; patent against &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt; and &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt;); in February 2017,  no briefing schedule for Dr Reddy’s motion to dismiss had yet been set. In December 2016, Horizon   filed a another complaint against  Dr Reddy’s for patent infringement of US-09393208 (Case IV). Later in December 2016, an initial case management conference was held for Case III against Dr Reddy's. In January 2017, a 6-day bench trial commenced against Dr Reddy's for Case I; in February 2017, closing arguments and post-trial filings had not yet been scheduled. At that time, scheduling orders for Case II and Case III were entered but a trial date had not yet been set [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;]. In April 2017, Dr Reddy's moved to dismiss claims related to the '621 patent against its second filed ANDA [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. In June 2017, the US District Court upheld the validity of two patents (US-08557285 and US-06926907) owned by a subsidiary of Aralez and licensed to Horizon and stated that Dr. Reddy's would infringe at least one of the two patents with their proposed generic products. The Court's judgment prevented Dr. Reddy's from launching generic versions in the US until at least the expiration of the relevant patent [&lt;ulink linkID="1941209" linkType="Reference"&gt;1941209&lt;/ulink&gt;], [&lt;ulink linkID="1941423" linkType="Reference"&gt;1941423&lt;/ulink&gt;]; in August 2017, Dr Reddy's filed a notice of appeal. Also in August  2017, the District Court granted Dr Reddy's motions to dismiss and later that month, the District Court stayed the claims involving the '636, '996, '190, '920, '888, and '695 patents pending the outcome of the appeal on the '907 and '285 patents. In March 2018, the cases were proceeding with respect to the remaining patents and the District Court had yet to set a trial date. In March 2018, the appeal was pending [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2011, Pozen and AstraZeneca received notice from Lupin of an ANDA for a generic version. Horizon and Pozen later filed suit against Lupin alleging infringement of &lt;ulink linkID="PA7789634" linkType="Patent"&gt;US-08852636&lt;/ulink&gt; and US-08858996. That complaint was later amended to include infringement allegations concerning US-08865190 [&lt;ulink linkID="1726316" linkType="Reference"&gt;1726316&lt;/ulink&gt;]. In July 2011, an Aralez subsidiary filed patent infringement lawsuits in a US District Court against Lupin related to the companies ANDA claiming infringement of US-08557285 and US-06926907 [&lt;ulink linkID="1941209" linkType="Reference"&gt;1941209&lt;/ulink&gt;], [&lt;ulink linkID="1941423" linkType="Reference"&gt;1941423&lt;/ulink&gt;]. In August 2015, Lupin filed petitions for inter partes (IPR) review of all challenged patents; in March 2016, the US Patent Trial and Appeal Board (PTAB) issued decisions to institute the IPRs for the US-08858996 and US-08865190 patents, and denied the petition for IPR of the US-08852636 patent. In February 2016, Horizon amended the complaint against Lupin to include infringement allegations concerning US-09161920 and US-9198888. In August 2016, Horizon filed new a complaint alleging infringement of US-08945621, US-09220698 and US-09345695 against Lupin. In November 2016, the PTAB hearings for the US-08858996 and US-08865190 patents were held; at that time, a final written decision on the IPRs for both patents by the PTAB was due no later than March 01, 2017. In December 2016, Horizon amended its complaint against Lupin to include infringement allegations concerning US-09393208. Later in December 2016, an initial case management conference was held for Case III against Lupin. In January 2017, Lupin entered into a stay pending the entry of judgment in Case I. At that time, scheduling orders for Case II and Case III were entered but a trial date had not yet been set [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;]. In June 2017, the US District Court upheld the validity of two patents (US-08557285 and US-06926907) and stated that Lupin would infringe at least one of the two patents with their proposed generic products. The Court's judgment prevented Lupin from launching generic versions in the US until at least the expiration of the relevant patent [&lt;ulink linkID="1941209" linkType="Reference"&gt;1941209&lt;/ulink&gt;], [&lt;ulink linkID="1941423" linkType="Reference"&gt;1941423&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, Pozen and AstraZeneca received notice from &lt;ulink linkID="1050004" linkType="Company"&gt;Anchen&lt;/ulink&gt; of an ANDA for a generic version. AstraZeneca and Pozen sued Anchen for infringement of US-06926907, US-06369085, &lt;ulink linkID="PA2967291" linkType="Patent"&gt;US-07411070&lt;/ulink&gt;, and &lt;ulink linkID="PA3699117" linkType="Patent"&gt;US-07745466&lt;/ulink&gt; [&lt;ulink linkID="1726316" linkType="Reference"&gt;1726316&lt;/ulink&gt;]. In June 2014, the litigation against Anchen was dismissed after Anchen recertified under Paragraph III [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, Pozen and AstraZeneca received notice from &lt;ulink linkID="26171" linkType="Company"&gt;Watson&lt;/ulink&gt;  of an ANDA for a generic version. In May 2015, Horizon sued &lt;ulink linkID="1088700" linkType="Company"&gt;Actavis&lt;/ulink&gt; (formerly Watson; now Allergan) for infringement of US-08852636 and US-08858996, That complaint was later amended to include infringement allegations concerning US-08865190 [&lt;ulink linkID="1726316" linkType="Reference"&gt;1726316&lt;/ulink&gt;]. In January 2016, Horizon filed another suit against Actavis for infringment of US-09161920 and US-9198888; the case was later consolidated with  the other case involving the three other challenged patents. In August 2016, Horizon filed new a complaint alleging infringement of US-08945621, US-09220698 and US-09345695 against Actavis. In December 2016, Horizon amended its complaint against Actavis to include infringement allegations concerning US-09393208. Later in December 2016, Actavis filed a motion to compel enforcement of settlement agreement related to Cases I, II and III, and a hearing was held; at that time,   the judge  recommended that Actavis’ motion to compel the enforcement of settlement should be granted. In January 2017, an order of dismissal was entered for all claims in Cases I, II and III. In January 2017, the lawsuit against Actavis was dismissed after a US District Court  granted Actavis’ motion to compel enforcement of a settlement agreement. In February 2017, Horizon appealed the dismissal decision to the US Court of Appeals [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;].  In March 2018, Horizon and Pozen entered into a confidential settlement agreement with Actavis granting Actavis a provisional license under the Orange Book listed patents to Vimovo, effective January 1, 2025. Pursuant to the terms of this agreement, the appeal and the underlying Vimovo cases against Actavis were dismissed [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2013, Pozen and AstraZeneca received notice from Mylan of an ANDA for a generic version. Horizon and Pozen filed suit against Mylan alleging infringement of US-08852636 and US-08858996. That complaint was later amended to include infringement allegations concerning US-08865190 [&lt;ulink linkID="1726316" linkType="Reference"&gt;1726316&lt;/ulink&gt;]. In June 2013, an Aralez subsidiary filed patent infringement lawsuits in a US District Court against Mylan related to the companies ANDA claiming infringement of US-08557285 and US-06926907 [&lt;ulink linkID="1941209" linkType="Reference"&gt;1941209&lt;/ulink&gt;], [&lt;ulink linkID="1941423" linkType="Reference"&gt;1941423&lt;/ulink&gt;]. In February 2016, Horizon amended the complaint against Mylan to include infringement allegations concerning US-09161920 and US-9198888. Later in February 2016, Mylan asserted a counterclaim for declaratory judgment of invalidity and non-infringement of US-09220698. In August 2016, Horizon filed new a complaint alleging infringement of US-08945621, US-09220698 and US-09345695 against Mylan. Later in August 2016, a US District Court entered an order denying Mylan's motion to consoliate Case I with Case II. In December 2016, Horizon amended its complaint against Mylan to include infringement allegations concerning US-09393208. Later in December 2016, an initial case management conference was held for Case III against Mylan [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;]. Also in December 2016, Mylan moved to dismiss claims related to the '621 patent against its ANDA [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. In January 2017, a 6-day bench trial commenced against Mylan for Case I; in February 2017, closing arguments and post-trial filings had not yet been scheduled. At that time, scheduling orders for Case II and Case III were entered but a trial date had not yet been set [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;]. In June 2017, the US District Court upheld the validity of two patents (US-08557285 and US-06926907)  and stated that Mylan would infringe at least one of the two patents with their proposed generic products. The Court's judgment prevented Mylan from launching generic versions in the US until at least the expiration of the relevant patent [&lt;ulink linkID="1941209" linkType="Reference"&gt;1941209&lt;/ulink&gt;], [&lt;ulink linkID="1941423" linkType="Reference"&gt;1941423&lt;/ulink&gt;]; in August 2017, Mylan filed a notice of appeal. Also in August  2017, the District Court granted Mylan's motions to dismiss and later that month, the District Court stayed the claims involving the '636, '996, '190, '920, '888, and '695 patents pending the outcome of the appeal on the '907 and '285 patents. In March 2018, the cases were proceeding with respect to the remaining patents and the District Court had yet to set a trial date. In March 2018, the appeal was pending [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. In May 2019, the US Court of Appeals for the Federal Circuit reversed the June 2017 decision by the US Disctrict Court for the District of New Jersey, involving the '907 and '285 patents, meaning the validity of the two patents was no longer upheld [&lt;ulink linkID="2152231" linkType="Reference"&gt;2152231&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2013, the Opposition Division of the EPO upheld the validity of &lt;ulink linkID="PA3318980" linkType="Patent"&gt;EP-01411900&lt;/ulink&gt;. The opposition proceedings related to combinations of proton pump inhibitors and NSAIDs, and, at that time, the opponent had until May 2013 to appeal [&lt;ulink linkID="1391296" linkType="Reference"&gt;1391296&lt;/ulink&gt;]. By March 2018, Aralez had issued patents in  Europe, including Norway, containing claims directed to certain compositions containing a combination of acid inhibitors (including PPIs) and NSAIDs, and to treatment methods involving the use of such compositions. The European patent is to expire in May 2022, but by that time, the compnay had obtained SPCs for Vimovo extending to dates between November 2025 and May 2026, depending on the country [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;Aralez owns issued Japanese patents containing claims directed to certain compositions containing a combination of acid inhibitors (including PPIs) and NSAIDs, and to treatment methods involving the use of such compositions. In March 2018, the company expected the patents outside of the US and Europe to expire in May 2022 [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;In January 2015, AstraZeneca received two notices of allegation from &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; in Canada. In response the company commenced proceedings in relation to &lt;ulink linkID="PA4127991" linkType="Patent"&gt;CA-02449098&lt;/ulink&gt; [&lt;ulink linkID="1745092" linkType="Reference"&gt;1745092&lt;/ulink&gt;]. A hearing was held in November 2017 [&lt;ulink linkID="1909620" linkType="Reference"&gt;1909620&lt;/ulink&gt;]. In February 2017, the Federal Court of Canada dismissed AstraZeneca's application. By March 2018, the Minister of Health had issued a marketing authorisation to Mylan [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;]. In March 2018, Aralez noted that together with AstraZeneca, a joint patent applications relating to Vimovo had been filed, and an issued Canadian patent related to the pharmacodynamics profile of Vimovo is to expire in June 2030; foreign counterparts, if granted, were expected to expire in September 2030.  Additionally, Aralez had also one issued Canadian patent related to methods of treatment with Vimovo in patients taking low dose aspirin, which is to expire as late as September  2029; any related patents issuing outside the US were expected to expire in September  2029. By March 2018, Aralez had issued patents in Australia, Canada, Europe, Eurasia, Israel, Mexico and Norway containing claims directed to certain compositions containing a combination of acid inhibitors (including PPIs) and NSAIDs, and to treatment methods involving the use of such compositions. In March 2018, the company expected the patents outside of the US and Europe to expire in May 2022 [&lt;ulink linkID="2014251" linkType="Reference"&gt;2014251&lt;/ulink&gt;]. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2009, POZEN filed a NDA with the FDA [&lt;ulink linkID="1022256" linkType="Reference"&gt;1022256&lt;/ulink&gt;], [&lt;ulink linkID="1022324" linkType="Reference"&gt;1022324&lt;/ulink&gt;]. The NDA was accepted for review in August 2009 [&lt;ulink linkID="1038587" linkType="Reference"&gt;1038587&lt;/ulink&gt;]; and in April 2010, the product received FDA approval  [&lt;ulink linkID="1095307" linkType="Reference"&gt;1095307&lt;/ulink&gt;]. By August 2010, POZEN had transferred ownership of the US regulatory filings to AstraZeneca [&lt;ulink linkID="1121093" linkType="Reference"&gt;1121093&lt;/ulink&gt;]. In July 2010, the drug was launched in the US [&lt;ulink linkID="1176104" linkType="Reference"&gt;1176104&lt;/ulink&gt;]. In November 2013,  Horizon acquired US marketing rights from Astrazeneca and POZEN  [&lt;ulink linkID="1500955" linkType="Reference"&gt;1500955&lt;/ulink&gt;], [&lt;ulink linkID="1500963" linkType="Reference"&gt;1500963&lt;/ulink&gt;]. In January 2014, Horizon launched Vimovo in the US [&lt;ulink linkID="1512497" linkType="Reference"&gt;1512497&lt;/ulink&gt;]. In June 2016, an sNDA was filed seeking approval  for the treatment of adolescent patients with JIA; in  July 2017, the drug was  approved  in that setting [&lt;ulink linkID="2095205" linkType="Reference"&gt;2095205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2009, an MAA was submitted to the EU via the decentralized procedure [&lt;ulink linkID="1050114" linkType="Reference"&gt;1050114&lt;/ulink&gt;]. In October 2010, the product received a positive opinion for approval in the EU; the Member States were to pursue national approvals [&lt;ulink linkID="1137778" linkType="Reference"&gt;1137778&lt;/ulink&gt;]. In November 2010, the drug was approved in the UK [&lt;ulink linkID="1147648" linkType="Reference"&gt;1147648&lt;/ulink&gt;]. By May 2011, the drug had been launched in the Netherlands [&lt;ulink linkID="1189017" linkType="Reference"&gt;1189017&lt;/ulink&gt;]. By July 2011, the drug was being marketed in nine European countries [&lt;ulink linkID="1210869" linkType="Reference"&gt;1210869&lt;/ulink&gt;].   In October 2011, the drug was launched in Norway [&lt;ulink linkID="1458974" linkType="Reference"&gt;1458974&lt;/ulink&gt;]. In April 2012, the drug was launched in Denmark [&lt;ulink linkID="1423886" linkType="Reference"&gt;1423886&lt;/ulink&gt;]. In November 2012, Vimovo was launched in Portugal [&lt;ulink linkID="1385565" linkType="Reference"&gt;1385565&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, the drug was launched in Switzerland by AstraZeneca for the treatment of OA, RA and AS [&lt;ulink linkID="1616731" linkType="Reference"&gt;1616731&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In April 2011, Health Canada approved the drug for the treatment of the signs and symptoms of OA, RA and AS, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers [&lt;ulink linkID="1186744" linkType="Reference"&gt;1186744&lt;/ulink&gt;]. By May 2011, the drug had been launched in Canada [&lt;ulink linkID="1189017" linkType="Reference"&gt;1189017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By February 2012,  drug launch was expected during 2012 in Mexico [&lt;ulink linkID="1260625" linkType="Reference"&gt;1260625&lt;/ulink&gt;]; however, no further development has been reported. &lt;/para&gt;&lt;para&gt;By March 2013, Vimovo had been launched in Brazil, Argentina and Columbia [&lt;ulink linkID="1396542" linkType="Reference"&gt;1396542&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;In January 2012, the drug was approved in Russia [&lt;ulink linkID="2074681" linkType="Reference"&gt;2074681&lt;/ulink&gt;]. By February 2012,  drug launch was expected during 2012 in Russia [&lt;ulink linkID="1260625" linkType="Reference"&gt;1260625&lt;/ulink&gt;]; launch presumably occurred later that year.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In October 2011, the TGA approved the drug in Australia as Vimovo. It is indicated for patients with an increased risk of gastrointestinal ulceration, who require NSAID therapy for symptomatic  management of  RA, OA and AS with an inflammatory component, and in whom lower doses of naproxen and other NSAIDS have proven inefficient [&lt;ulink linkID="1753868" linkType="Reference"&gt;1753868&lt;/ulink&gt;].  By February 2012,  launch was expected in Australia in 2012  [&lt;ulink linkID="1260625" linkType="Reference"&gt;1260625&lt;/ulink&gt;]. However, no further development has been reported and by September 2018, the drug had still not been launched in Australia [&lt;ulink linkID="2074689" linkType="Reference"&gt;2074689&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2012, the drug had been launched in the Philippines [&lt;ulink linkID="1260625" linkType="Reference"&gt;1260625&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;By February 2012, the drug had been launched in New Zealand [&lt;ulink linkID="1260625" linkType="Reference"&gt;1260625&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In January 2012, the combination was approved in Korea [&lt;ulink linkID="1660566" linkType="Reference"&gt;1660566&lt;/ulink&gt;]. By September 2012, the combination was available in Korea  [&lt;ulink linkID="1333692" linkType="Reference"&gt;1333692&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label contains a black box warning highlighting the increased risk of cardiovascular and gastrointestinal adverse events [&lt;ulink linkID="1095696" linkType="Reference"&gt;1095696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In April 2012, an open-label, single-group assignment, safety, phase IV trial (&lt;ulink linkID="85364" linkType="Protocol"&gt;NCT01544114&lt;/ulink&gt;; D1120C00037) began in patients (expected n = 60) in the US with in adolescents aged 12 to 16 years with juvenile idiopathic arthritis. The primary endpoints were the incidence of adverse and serious adverse events at 1, 3 and 6 months, change in serum iron/total iron binding capacity, vitamin b12 and magnesium, and change from baseline in vital signs, physical examination results and laboratory tests. At that time, the trial was estimated to complete in June 2013 [&lt;ulink linkID="1394393" linkType="Reference"&gt;1394393&lt;/ulink&gt;].  In February 2015, the study was completed  [&lt;ulink linkID="1394393" linkType="Reference"&gt;1394393&lt;/ulink&gt;].   In June 2018, results were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. Eligible subjects (n = 46) received naproxen/esomeprazole magnesium based on baseline weight: minimum and maximum dose levels administered were 250/20 mg and 250/20 mg in patients with baseline weight &amp;lt; 38 kg; 250/20 mg and 375/20 mg in those with baseline weight 38 to &amp;lt; 50 kg; 375/20 mg and 500/20 mg in patients weighing 50 to &amp;lt; 75 kg; and 500/20 mg and 500/20 mg in those weighing &amp;gt;/= 75 kg, respectively. In the naproxen/esomeprazole magnesium 250/20, 375/20 and 500/20 mg groups, the proportion of patients achieving American College of Rheumatology (ACR) 30 response at last visit was 4, 17 and 21%; those attaining ACR 50 response was 4, 17 and 21%; those achieving ACR 70 response was 4, 17 and 21 and those attaining ACR 90 response was 4, 17 and 21%, respectively. Dose-related efficacy effect was not observed. At least one treatment-emergent adverse event was reported by 80.4% of patients [&lt;ulink linkID="2045178" linkType="Reference"&gt;2045178&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2012, a filing to conduct a clinical trial in China was submitted with the SFDA, presumed to be for use in patients with OA, RA and AS. However, in August 2012, the application process was discontinued [&lt;ulink linkID="1342686" linkType="Reference"&gt;1342686&lt;/ulink&gt;], [&lt;ulink linkID="1350768" linkType="Reference"&gt;1350768&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2008, the FDA notified the companies that it would conduct a review on the acceptability of endoscopic gastric ulcers as a primary endpoint in clinical trials of Vimovo [&lt;ulink linkID="953351" linkType="Reference"&gt;953351&lt;/ulink&gt;]. In January 2009, the FDA completed its review and indicated that the primary endpoint of gastric ulcer incidence was acceptable in clinical studies  [&lt;ulink linkID="979948" linkType="Reference"&gt;979948&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2008, phase III trials evaluating Vimovo  in patients with OA of the knee began (&lt;ulink linkID="22095" linkType="Protocol"&gt;NCT00665431&lt;/ulink&gt;; &lt;ulink linkID="22096" linkType="Protocol"&gt;NCT00664560&lt;/ulink&gt;; PN400-307 &amp;amp; 309). The randomized, double-blind, placebo-controlled studies was to enroll patients to receive Vimovo twice-daily or &lt;ulink linkID="12135" linkType="Drug"&gt;Celecoxib&lt;/ulink&gt; once-daily [&lt;ulink linkID="968495" linkType="Reference"&gt;968495&lt;/ulink&gt;], [&lt;ulink linkID="968498" linkType="Reference"&gt;968498&lt;/ulink&gt;]. In December 2008, the trials were ongoing [&lt;ulink linkID="968356" linkType="Reference"&gt;968356&lt;/ulink&gt;]; in March 2009, the trials were completed [&lt;ulink linkID="968495" linkType="Reference"&gt;968495&lt;/ulink&gt;], [&lt;ulink linkID="968498" linkType="Reference"&gt;968498&lt;/ulink&gt;]. In November 2014, pooled data were presented at the 78th ACR Annual Meeting in Boston, MA. At week 12, PGA-VAS, WOMAC pain, WOMAC function scores mean change from baseline was -43.1, -37.6 and 25, respectively in the naproxen + esomeprazole group compared with celecoxib group (-42.3, -36.6 and 23.6, respectively) and placebo (-37, -31.5 and 17.9, respectively) [&lt;ulink linkID="1609133" linkType="Reference"&gt;1609133&lt;/ulink&gt;] [&lt;ulink linkID="1613906" linkType="Reference"&gt;1613906&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In September 2007, a comparative, open-label, phase III trial (&lt;ulink linkID="11353" linkType="Protocol"&gt;NCT00527904&lt;/ulink&gt;; PN400-304) was initiated in the US in patients with  OA, RA, AS, or other conditions requiring daily NSAID therapy, who were at risk for NSAID-associated gastric ulcers either due to age (&amp;gt;/= 50 years) or history of ulcer in the past 5 years   (expected n = 400). The primary endpoint was long-term safety [&lt;ulink linkID="833069" linkType="Reference"&gt;833069&lt;/ulink&gt;]. In March 2011, data were published and presented at the American Academy of Pain Medicine Annual Meeting in National Harbor, MD. The product was generally well tolerated and no new or unexpected safety issues were observed [&lt;ulink linkID="1179279" linkType="Reference"&gt;1179279&lt;/ulink&gt;], [&lt;ulink linkID="1179478" linkType="Reference"&gt;1179478&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2007,  randomized, double-blind, phase III trials (&lt;ulink linkID="22616" linkType="Protocol"&gt;NCT00527787&lt;/ulink&gt;; PN400-301 &amp;amp; 302) were initiated in subjects (expected n = 400) at risk of developing NSAID-associated ulcers in the US. The subjects were to receive Vimovo or 500 mg of naproxen, twice-daily for 6 months. The primary endpoint was occurrence of gastric ulcer [&lt;ulink linkID="833071" linkType="Reference"&gt;833071&lt;/ulink&gt;]. By May 2008, enrollment in the trial was complete [&lt;ulink linkID="903881" linkType="Reference"&gt;903881&lt;/ulink&gt;]. In December 2008, results showed Vimovo significantly reduced the incidence of gastric ulcers compared with treatment with naproxen alone [&lt;ulink linkID="968356" linkType="Reference"&gt;968356&lt;/ulink&gt;], [&lt;ulink linkID="968339" linkType="Reference"&gt;968339&lt;/ulink&gt;]. Further data were reported in October 2009 at the American College of Rheumatology meeting in Philadelphia, PA. Overall incidence of gastric ulcers (GU) in study 301 was 4.1% in patients given Vimovo and 23.1% in patients given enteric coated (EC) naproxen; in study 302, incidence of gastric ulcers in patients given Vimovo was 7.1% and in patients given EC naproxen was 24.3%. In patients taking low-dose aspirin, the incidence of GU in the Vimovo arm was 3%, compared with 28.4% for patients on EC naproxen. In patients not taking low-dose aspirin GU, incidence was 6.4% and 22.2% in the Vimovo and enteric coated naproxen arms, respectively. In study 301 incidence of duodenal ulcers was 0.5% in the Vimovo arm and 5.1% in the naproxen arm; in study 302, the respective incidences were 1% and 5.7%. Gastritis, dyspepsia, erosive duodentis and erosive gastritis were less frequent in the Vimovo arms [&lt;ulink linkID="1050342" linkType="Reference"&gt;1050342&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2008, the Pediatric Committee of the EMA recommended that the obligation to submit data obtained through clinical studies with children be waived for the drug in the areas of immunology and rheumatology [&lt;ulink linkID="940263" linkType="Reference"&gt;940263&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-07-31T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-07-31T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2018-12-31T00:00:00.000Z</StatusDate><Source id="2107401" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-07-31T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2010-08-03T00:00:00.000Z</StatusDate><Source id="1121093" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2010-08-03T00:00:00.000Z</StatusDate><Source id="1121093" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2010-08-03T00:00:00.000Z</StatusDate><Source id="1121093" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2010-08-03T00:00:00.000Z</StatusDate><Source id="1121093" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-08-03T00:00:00.000Z</StatusDate><Source id="1121093" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25618">POZEN Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2006-08-02T00:00:00.000Z</StatusDate><Source id="681634" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-12-03T00:00:00.000Z</StatusDate><Source id="2100924" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1342686" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-01-19T00:00:00.000Z</StatusDate><Source id="1660566" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-01-19T00:00:00.000Z</StatusDate><Source id="1660566" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-01-19T00:00:00.000Z</StatusDate><Source id="1660566" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2010-07-31T00:00:00.000Z</StatusDate><Source id="1176104" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-01-12T00:00:00.000Z</StatusDate><Source id="2074681" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-01-12T00:00:00.000Z</StatusDate><Source id="2074681" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-01-12T00:00:00.000Z</StatusDate><Source id="2074681" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-10-18T00:00:00.000Z</StatusDate><Source id="1753868" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-10-18T00:00:00.000Z</StatusDate><Source id="1753868" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-10-18T00:00:00.000Z</StatusDate><Source id="1753868" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1394393" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2017-07-06T00:00:00.000Z</StatusDate><Source id="2095205" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-05-05T00:00:00.000Z</StatusDate><Source id="1189017" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-07-01T00:00:00.000Z</StatusDate><Source id="1616731" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-07-01T00:00:00.000Z</StatusDate><Source id="1616731" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-07-01T00:00:00.000Z</StatusDate><Source id="1616731" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-09-01T00:00:00.000Z</StatusDate><Source id="1333692" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-09-01T00:00:00.000Z</StatusDate><Source id="1333692" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-10-01T00:00:00.000Z</StatusDate><Source id="1458974" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-10-01T00:00:00.000Z</StatusDate><Source id="1458974" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-10-01T00:00:00.000Z</StatusDate><Source id="1458974" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-11-15T00:00:00.000Z</StatusDate><Source id="1385565" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-11-15T00:00:00.000Z</StatusDate><Source id="1385565" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3003">Juvenile rheumatoid arthritis</Indication><StatusDate>2017-07-06T00:00:00.000Z</StatusDate><Source id="2095205" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-11-15T00:00:00.000Z</StatusDate><Source id="1385565" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1423886" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1423886" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1423886" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2011-07-28T00:00:00.000Z</StatusDate><Source id="1210869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-02-06T00:00:00.000Z</StatusDate><Source id="1260625" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2013-03-25T00:00:00.000Z</StatusDate><Source id="1396542" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="2074681" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="2074681" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="2074681" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2012-09-01T00:00:00.000Z</StatusDate><Source id="1333692" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-01-02T00:00:00.000Z</StatusDate><Source id="1512497" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2013-11-22T00:00:00.000Z</StatusDate><Source id="2011763" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2006-08-02T00:00:00.000Z</StatusDate><Source id="681634" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2006-08-02T00:00:00.000Z</StatusDate><Source id="681634" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2006-08-02T00:00:00.000Z</StatusDate><Source id="681634" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2006-08-02T00:00:00.000Z</StatusDate><Source id="681634" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2007-09-10T00:00:00.000Z</StatusDate><Source id="833071" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2007-09-10T00:00:00.000Z</StatusDate><Source id="833071" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2007-09-10T00:00:00.000Z</StatusDate><Source id="833071" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2007-09-10T00:00:00.000Z</StatusDate><Source id="833071" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2007-02-01T00:00:00.000Z</StatusDate><Source id="762824" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2007-02-01T00:00:00.000Z</StatusDate><Source id="762824" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2007-02-01T00:00:00.000Z</StatusDate><Source id="762824" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2007-02-01T00:00:00.000Z</StatusDate><Source id="762824" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2009-06-30T00:00:00.000Z</StatusDate><Source id="1022256" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2009-06-30T00:00:00.000Z</StatusDate><Source id="1022256" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25618">POZEN Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2009-06-30T00:00:00.000Z</StatusDate><Source id="1022256" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2009-06-30T00:00:00.000Z</StatusDate><Source id="1022256" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate><Source id="1095307" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-04-27T00:00:00.000Z</StatusDate><Source id="1186744" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2011-04-27T00:00:00.000Z</StatusDate><Source id="1186744" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2010-11-12T00:00:00.000Z</StatusDate><Source id="1147648" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2010-11-12T00:00:00.000Z</StatusDate><Source id="1147648" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2010-11-12T00:00:00.000Z</StatusDate><Source id="1147648" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2011-04-27T00:00:00.000Z</StatusDate><Source id="1186744" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2009-10-16T00:00:00.000Z</StatusDate><Source id="1050114" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2009-10-16T00:00:00.000Z</StatusDate><Source id="1050114" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2009-10-16T00:00:00.000Z</StatusDate><Source id="1050114" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2009-10-16T00:00:00.000Z</StatusDate><Source id="1050114" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00535"><Name>Cyclooxygenase</Name><SwissprotNumbers/></Target><Target id="PTGT-00898"><Name>H+ K+ ATPase</Name><SwissprotNumbers><Swissprot>P09626</Swissprot><Swissprot>P18434</Swissprot><Swissprot>P18597</Swissprot><Swissprot>P18598</Swissprot><Swissprot>P19156</Swissprot><Swissprot>P20648</Swissprot><Swissprot>P27112</Swissprot><Swissprot>P33704</Swissprot><Swissprot>P50992</Swissprot><Swissprot>P50996</Swissprot><Swissprot>P51164</Swissprot><Swissprot>Q64436</Swissprot><Swissprot>Q92126</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2164896" linkType="reference" linkID="2164896"&gt;2164896&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1053335">Horizon Pharma plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1067362">Vidara Therapeutics LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1110015">Old API Wind-down Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="15713">Nuvo Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16587">Grunenthal GmbH</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22235">LG Chem Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>2</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>0</CountActive><CountInactive>3</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O</Smiles><Smiles>Cc1cnc(c(c1OC)C)C[S@](=O)c2[nH]c3ccc(cc3n2)OC</Smiles><Smiles>Cc1cnc(c(c1OC)C)C[S@](=O)c2[nH]c3ccc(cc3n2)OC.C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O</Smiles><Smiles>Cc1cnc(c(c1OC)C)C[S@](=O)c2[n-]c3ccc(cc3n2)OC.Cc1cnc(c(c1OC)C)C[S@](=O)c2[n-]c3ccc(cc3n2)OC.C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O.[Mg+2]</Smiles></StructureSmiles><Deals><Deal id="109118" title="POZEN and AstraZeneca to codevelop PN-400 combination tablet for pain and inflammation  "/><Deal id="132624" title="US Government to fund POZEN's development of VIMOVO, PA-32540 and PA-65020"/><Deal id="142323" title="LG Life Sciences to copromote AstraZeneca's Vimovo in Korea"/><Deal id="147403" title="Horizon Pharma acquires AstraZeneca's VIMOVO in US    "/><Deal id="164232" title="Purchase of VIMOVO (naproxen/esomeprazole) delayed-release tablet, for pain, in the U.S. "/><Deal id="166127" title="Reverse merger with Horizon Pharma for $660M in cash and stock"/><Deal id="191643" title="Tribute Pharmaceuticals merges with POZEN"/><Deal id="249146" title="Nuvo Pharmaceuticals acquires Aralez's Canadian specialty pharmaceutical business and its royalties    "/><Deal id="250841" title="Grunenthal acquires worldwide rights of AstraZeneca's Vimovo for inflammatory diseases excluding US and Japan "/></Deals><PatentFamilies><PatentFamily id="1113858" number="WO-2010151216" title="Method for treating a patient at risk for developing an NSAID-associated ulcer"/><PatentFamily id="204283" number="WO-09725064" title="Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID."/><PatentFamily id="2348449" number="CU-20110050" title="M??todo de administraci??n de una composici??n farmac??utica a un paciente que lo necesita"/><PatentFamily id="2473659" number="WO-09427988" title="Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds"/><PatentFamily id="2497153" number="WO-2010029335" title="Method for delivering a pharmaceutical composition to patient in need thereof"/><PatentFamily id="275239" number="WO-02098352" title="Pharmaceutical compositions for the coordinated delivery of NSAIDs"/><PatentFamily id="468142" number="WO-09854171" title="Novel form of S-omeprazole."/><PatentFamily id="833963" number="WO-09501977" title="Magnesium omeprazole."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Strawman Ltd" id="1002504"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daiichi Sankyo Co Ltd" id="1017506"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amneal Pharmaceuticals Inc" id="1027030"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Farmaprojects SA" id="1030694"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Acino Holding AG" id="1040020"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Horizon Pharma plc" id="1053335"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chatfield Pharmaceuticals Limited" id="1057077"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pinewood Laboratories Limited" id="1060163"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanmi Holdings Co Ltd" id="1060189"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Consilient Health Limited" id="1095269"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Old API Wind-down Ltd" id="1110015"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daewoong Pharmaceutical Co Ltd" id="15587"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nuvo Pharmaceuticals Inc" id="15713"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Krka dd Novo Mesto" id="17690"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stada Arzneimittel AG" id="20236"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ethypharm SA" id="21952"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>